Clinical trials: Prostatic Adenocarcinoma
Prostate Adenocarcinoma
Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
This phase 2 trial studies radium Ra 223 dichloride, hormone therapy and stereotactic body radiation in treating patients with prostate cancer that has spread to other places in the body.
- Trial name
- NCT03361735
- Testing
- Leuprolide Acetate, Goserelin Acetate, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- City of Hope Medical Center
Prostate Adenocarcinoma
ERG Protein Expression in Prostatic Adenocarcinoma and Its Clinicopathological Features
Evaluation the ERG expression in prostatic acinar adenocarcinoma and its association with clinicopathological features.
- Trial name
- NCT04825691
- Testing
- Immunohistochemistry of prostate biopsy
- Volunteers
- 50 people
- Sponsor
- Assiut University
Prostate Adenocarcinoma
Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer
1. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a PSMA PET whole-body tumor burden classification was constructed to guide treatment and evaluate prognosis. 2.
- Trial name
- NCT06387238
- Testing
- PSMA PET/CT
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
Prostate Cancer
Radiation Therapy in Treating Patients With Relapsed Prostate Cancer After Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating patients with relapsed prostate cancer.
- Trial name
- NCT01272050
- Testing
- radiation therapy
- Where
- 28 sites in Belgium, Germany and 1 more
- Volunteers
- 350 people
- Sponsor
- Swiss Cancer Institute
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men…
- Trial name
- CONTACT-02 (NCT04446117)
- Testing
- Cabozantinib, Atezolizumab, Abiraterone Acetate
- Where
- 280 sites in United States, Argentina and 25 more
- Volunteers
- 575 people
- Sponsor
- Exelixis
Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma
Stereotactic Body Radiation Therapy With Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients With Prostate Cancer
This phase I/II trial studies the side effects and best dose of stereotactic body radiation therapy while using intensity-modulated radiation therapy (IMRT) planning to help avoid radiation to normal tissue in patients with…
- Trial name
- NCT02470897
- Testing
- Radiation Therapy Treatment Planning and Simulation, SBRT
- Where
- 3 sites in United States
- Volunteers
- 115 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
To determine if dexamethasone or dexamethasone plus metronidazole restore sensitivity to abiraterone for the treatment of metastatic prostate cancer.
- Trial name
- NCT06616597
- Testing
- Abiraterone acetate, Dexamethasone, Metronidazole
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
This study is being conducted to learn more about the safety, tolerability, and effectiveness of an experimental treatment for metastatic prostate cancer called AZD6621.
- Trial name
- ACTIVATED-4-PC (NCT07192614)
- Testing
- AZD6621
- Where
- 26 sites in United States, Belgium and 7 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
Prostate Cancer
Comparison of Two Radiation Therapy Regimens in Treating Patients With Stage II or Stage III Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources of radiation to kill tumor cells. It is not yet known which radiation therapy regimen is more effective in treating prostate cancer.
- Trial name
- NCT00062309
- Testing
- radiation therapy
- Where
- United States
- Volunteers
- 307 people
- Sponsor
- Fox Chase Cancer Center
Prostate Cancer
Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer
RATIONALE: Androgens can stimulate the growth of prostate cancer cells. Drugs such as flutamide and buserelin may stop the adrenal glands from producing androgens.
- Trial name
- NCT00054106
- Testing
- buserelin, custirsen sodium, flutamide
- Where
- Canada
- Volunteers
- 25 people
- Sponsor
- NCIC Clinical Trials Group
Prostate Cancer
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT01083368
- Testing
- temsirolimus, bevacizumab, polymorphism analysis
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Case Comprehensive Cancer Center
Cancer
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either…
- Trial name
- NCT04485013
- Testing
- TTX-080, pembrolizumab, cetuximab
- Where
- 41 sites in United States
- Volunteers
- 240 people
- Sponsor
- Tizona Therapeutics, Inc
Prostate Adenocarcinoma
Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
The goal of this clinical trial is to study definitive external beam radiation therapy together with drugs called androgen deprivation therapy (ADT) in patients with prostate cancer.
- Trial name
- SENTRY (NCT07364071)
- Testing
- Radiation therapy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of California, San Diego
Prostate Cancer (Adenocarcinoma)
Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses
This study aims to help patients with prostate cancer and their spouses cope better with the challenges of cancer by learning and supporting each other together.
- Trial name
- NCT07196488
- Testing
- Dyadic Co-learning Intervention
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Prostate Cancer Recurrent, Prostate Cancer
Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer
The purpose of this phase I/Ib study is to determine the safety profile of Epidiolex (CBD oil) in biochemically recurrent prostate cancer patients. The study consists of a dose escalation part and dose expansion part.
- Conditions
- Prostate Cancer Recurrent, Prostate Cancer, Prostate Adenocarcinoma
- Trial name
- NCT04428203
- Testing
- Epidiolex Oral Liquid Product
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Zin W Myint
Prostate Cancer
Study of Hypo-fractionated Proton Radiation for Low Risk Prostate Cancer
The purpose of this study is to compare the effects (good and bad) on patients with prostate cancer by comparing the standard dose of radiation therapy (44 treatments over 8½-9 weeks) with a higher daily dose of radiation (5…
- Trial name
- NCT01230866
- Testing
- Proton Radiation Hypofractionation, Proton Radiation Standard Fractionation
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Proton Collaborative Group
Prostate Cancer, Prostate Adenocarcinoma
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
To determine the effects of exercise therapy on molecular, radiologic, and pathologic nimbosus hallmarks versus usual care control in men on Active Surveillance for localized prostate cancer.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
- Trial name
- NCT05751434
- Testing
- Exercise Therapy
- Where
- 10 sites in United States
- Volunteers
- 102 people
- Sponsor
- City of Hope Medical Center
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer
Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer
This phase II trial studies how well linsitinib works in treating patients with asymptomatic or mild symptomatic metastatic prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT01533246
- Testing
- linsitinib, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Adenocarcinoma of the Prostate, Stage III Prostate Cancer
Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer
RATIONALE: Antineoplastons are naturally occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells.
- Conditions
- Adenocarcinoma of the Prostate, Stage III Prostate Cancer, Stage IV Prostate Cancer, Recurrent Prostate Cancer
- Trial name
- NCT00003517
- Testing
- antineoplaston A10, antineoplaston AS2-1, bicalutamide
- Where
- United States
- Sponsor
- Burzynski Research Institute
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.